Area of research
Oncology · Cancer Research
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, and Cancer Research and Treatments.
Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer
Pancreatic cancer–restricted cryptic antigens are targets for T cell recognition
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer
Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Cancer tissue of origin constrains the growth and metabolism of metastases
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.
A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with <i>KRAS</i><i><sup>G12D</sup></i> mutation.
<i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias
Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer
Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment
Translational advances in pancreatic ductal adenocarcinoma therapy
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity
Structure–function analysis of the SHOC2–MRAS–PP1C holophosphatase complex
Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS–MAPK Pathway Inhibition in Pancreatic Cancer
Spatially organized multicellular immune hubs in human colorectal cancer
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps
SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization
Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection
Abstract PR-006: Integrative genomic characterization of therapeutic targets for pancreatic cancer